Phase I Safety and Immunogenicity Trial of an Investigational RNActive Rabies Vaccine (CV7201) in Healthy Adults

Trial Profile

Phase I Safety and Immunogenicity Trial of an Investigational RNActive Rabies Vaccine (CV7201) in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Nadorameran (Primary) ; Nadorameran (Primary)
  • Indications Rabies
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors CureVac
  • Most Recent Events

    • 27 Jul 2017 Results published in the Internet Document
    • 11 Jan 2017 Interim results published in a CureVac media release.
    • 11 Jan 2017 Interim results presented at the 35th Annual J.P. Morgan Healthcare Conference, as per a CureVac media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top